

## Remarks

Claims 1-6, 8-16, 18 and 19 were pending.

Claims 1 and 8 are amended.

Claim 2 is original.

Claims 3- 6 and 18-19 are as previously presented.

Claims 9-16 are withdrawn.

The application now contains claims 1-6, 8-16, 18 and 19.

Claim 1 is amended for clarity by deleting the word "radical" and inserting in its stead the word "group". Support is inherent in the claim and specification and Applicants' meaning of the original wording is exemplified in claim 6 and example 2 on page 11 of the specification.

Claim 8, presently withdrawn by the Examiner, is likewise amended for clarity by deleting the word "radical" and inserting in its stead the word "group".

No new matter is added.

## Rejections

Claims 1-6 and 18-19 are rejected under 35 USC 112 second paragraph for being unclear regarding the meaning of the word "radical". The Examiner asks whether this refers to a group of formula 1a, or an analog derivative of such a group. The instant amendments replace the word "radical" with group to avoid any confusion that the substituent in question is a group of formula 1a, connected to the structure of formula 1a at the position designated by the dotted line. Applicants believe that while the word "group" was not used in the specification, the meaning of the terms in question are exemplified in claim 6 and example 2 on page 11 of the specification.


Applicants respectfully submit that the above amendments have addressed and overcome the rejections and kindly ask that they be withdrawn and claims 1-6, 18 and 19 be found allowable.

Applicants also respectfully note that all claims, including withdrawn claims 8-16 as instantly amended, refer only to the novel compounds of instantly amended claim 1 which Applicants respectfully submit constitutes a unifying technical feature under PCT rules. Applicants also respectfully refer to the "Advisory of Rejoinder" in the Restriction Requirement of June 19, 2007.

Applicants therefore further kindly ask that upon finding claims 1-6, 18 and 19 allowable that the Examiner rejoin claims 8-16 in their present form and find them also allowable.

In the event that minor amendments will further prosecution, Applicants request that the Examiner contact the undersigned representative.

Respectfully submitted,



Joseph C. Suhadolnik  
Agent for Applicants  
Reg. No. 56,880  
filed under 37 CFR 1.34(a)

Ciba Specialty Chemicals Corporation  
Patent Department  
540 White Plains Road  
P.O. Box 2005  
Tarrytown, NY 10591-9005  
Tel. (914) 785-2973  
Fax (914) 785-7102